Tesnatilimab
- Generic Name
- Tesnatilimab
- Drug Type
- Biotech
- CAS Number
- 2242758-08-1
- Unique Ingredient Identifier
- 2B860WP9F0
- Background
Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
A Study of JNJ-64304500 in Participants With Alopecia Areata
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04740970
- Locations
- 🇯🇵
The Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan
🇯🇵Yamaguchi University Hospital, Ube, Japan
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04712006
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT04667052
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
Phase 2
Withdrawn
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04655807
- Locations
- 🇺🇸
Medisphere Medical Research Center, Llc, Evansville, Indiana, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 48
- Registration Number
- NCT03002025
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 388
- Registration Number
- NCT02877134
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath